Drug Trial Radar · NCT06229288
Amoxicillin Alone Versus Amoxicillin/Clavulanate for Community-acquired Pneumonia in Patients Aged 65 Years or Older, and Hospitalized in a Non-intensive Care Unit Ward
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
326
Planned (sponsor's estimate)
Start
Apr 25, 2024
Primary completion
May 25, 2027
Study completion May 25, 2027
Sponsor
- Lead sponsor
- Nantes University HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Reduce inappropriate antibiotic use is a priority of public health agencies. Community-acquired pneumonia (CAP) is one of the most important indications for antibiotic prescriptions. In the majority of the studies of CAP, there is a large proportion of cases with no pathogen identified. Thus, the choice of the empirical antibiotic depends on the most likely pathogen, individual risk factors, comorbidities, and allergies. Patients aged 65 years or older are often treated with amoxicillin/clavulanate or with another broad-spectrum antibiotic (third-generation cephalosporins, antipneumococcal fluoroquinolone). However, broad-spectrum antibiotic prescription in CAP is debated and concerns exist about side-effects and selective pressure for resistance. Due to lack of head-to-head antibiotic comparisons, a recent Cochrane review concluded that current evidence from Randomized Clinical Trials (RCTs) is insufficient to make evidence-based recommendations for the choice for antibiotic to be used, highlighting an important evidence gap.
Conditions
- Community-acquired Pneumonia
Interventions
AmoxicillinDrug
Participants will be randomized to IV/oral amoxicillin or IV/oral amoxicillin/clavulanate for 5 days. Both agents are approved for treatment of respiratory infections. Amoxicillin PO: The dose is two capsule of 500 mg every 8 hours (that is 3 times daily). Amoxicillin IV: The dose is 1 g every 8 hours (that is 3 times daily)
Amoxicillin/clavulanateDrug
Participants will be randomized to IV/oral amoxicillin or IV/oral amoxicillin/clavulanate for 5 days. Both agents are approved for treatment of respiratory infections. Amoxicillin/clavulanate PO: The dose is two tablets of 500 mg/62.5 mg every 8 hours (that is 3 times daily, approved standard dose) Amoxicillin/clavulanate IV: The dose is 1 g/200 mg every 8 hours (that is 3 times daily, approved standard dose)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Non-inferiorityTime frame: Day 30 after inclusion (=Day 1)
Locations
19 sites in 1 country. Site status is shown where the registry gives one.
Chu Angers
Angers, France · Recruiting
CHU Angers
Angers, France · Recruiting
CHU Avicenne AP-HP
Bobigny, France · Recruiting
CHU Avicenne AP-HP
Bobigny, France · Recruiting
CHRU Brest
Brest, France · Recruiting
CHRU Brest
Brest, France · Recruiting
CHD Vendée
La Roche-sur-Yon, France · Recruiting
CHD Vendée
La Roche-sur-Yon, France · Recruiting
CHU Grenoble-Alpes
La Tronche, France · Recruiting
CHU Grenoble-Alpes
La Tronche, France · Recruiting
Assistance Publique Hopitaux De Marseille
Marseille, France · Recruiting
CHU de Nantes
Nantes, France · Recruiting
CH Perigueux
Périgueux, France · Recruiting
CH Saint-Nazaire
Saint-Nazaire, France · Recruiting
CH Saint-Nazaire
Saint-Nazaire, France · Recruiting
CHRU - TOULOUSE Hôpital Purpan
Toulouse, France · Recruiting
CHRU - TOULOUSE Hôpital Purpan
Toulouse, France · Recruiting
CHRU TOULOUSE - Hôpital Rangueuil
Toulouse, France · Recruiting
Centre Hospitalier Bretagne Atlantique
Vannes, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.